SignalXSignalX

PRAX Praxis Precision Medicines, Inc.

Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Praxis Precision Medicines, Inc. Overview

Praxis Precision Medicines, Inc. (PRAX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • No new or changed risk factors compared to 10-K filed February 28, 2025
  • • Clinical trial outcomes and regulatory approval remain key risks for near-term operational performance
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$0

▼ -100.0% YoY

Net Income

-$74M

▼ -42.4% YoY▼ -3.9% QoQ

ROE

-21.5%

Total Assets

$396M

EPS (Diluted)

$-3.37

▼ -20.4% YoY▼ -1.8% QoQ

Operating Cash Flow

-$65M

▼ -136.6% YoY▼ -19.0% QoQ

Source: XBRL data from Praxis Precision Medicines, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Praxis Precision Medicines, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.